Story perspectives

Eli Lilly and Alchemab Unite for $415M ALS Breakthrough

5/7/2025

23 4

Summary

Lilly Partners for ALS

Eli Lilly has joined forces with UK-based Alchemab in a groundbreaking licensing deal valued at up to $415 million for ATLX-1282, an innovative antibody therapy aimed at combating ALS. Alchemab will spearhead early trials, while Lilly takes the reins in later stages, marking a significant step forward in the fight against this challenging disease.

Summary

Pagan Innovates Parkinson's Treatment

At the 2025 American Academy of Neurology Annual Meeting, Dr. Fernando L. Pagan unveiled groundbreaking advancements in Parkinson's disease treatment. He championed outpatient subcutaneous infusions and nurse-led titration, shifting focus from traditional hospital protocols. Additionally, he introduced an exciting once-daily therapy combining rasagiline and pramipexole, offering newly diagnosed patients enhanced symptom control with reduced dosages.

History

Historical Context

Eli Lilly's $415 million partnership with Alchemab for ALS therapy echoes the surge in ALS research funding following the 2014 Ice Bucket Challenge. This viral campaign raised $220 million, significantly boosting ALS research and leading to breakthroughs, including the recent approval of AMX0035, highlighting the impact of public engagement on medical advancements.

1 of 3

Lilly Partners for ALS

Eli Lilly has joined forces with UK-based Alchemab in a groundbreaking licensing deal valued at up to $415 million for ATLX-1282, an innovative antibody therapy aimed at combating ALS. Alchemab will spearhead early trials, while Lilly takes the reins in later stages, marking a significant step forward in the fight against this challenging disease.

1 / 3